S
TBPH icon

SignatureFD’s Theravance Biopharma TBPH Stock Holding History

SignatureFD’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58K Sell
387
-113
-23% -$1.87K ﹤0.01% 2782
2026
Q1 		$8.12K Sell
500
-32
-6% -$566 ﹤0.01% 2598
2025
Q4 		$9.95K Buy
532
+447
+526% +$7.42K ﹤0.01% 2434
2025
Q3 		$1.24K Hold
85
– – ﹤0.01% 3043
2025
Q2 		$938 Hold
85
– – ﹤0.01% 3034
2025
Q1 		$759 Hold
85
– – ﹤0.01% 3105
2024
Q4 		$800 Hold
85
– – ﹤0.01% 3068
2024
Q3 		$685 Sell
85
-232
-73% -$2.01K ﹤0.01% 3056
2024
Q2 		$2.69K Sell
317
-269
-46% -$2.43K ﹤0.01% 2683
2024
Q1 		$5.26K Sell
586
-122
-17% -$1.13K ﹤0.01% 2516
2023
Q4 		$7.96K Buy
708
+554
+360% +$5.58K ﹤0.01% 2355
2023
Q3 		$1.33K Sell
154
-13
-8% -$126 ﹤0.01% 2881
2023
Q2 		$1.73K Sell
167
-10
-6% -$110 ﹤0.01% 2851
2023
Q1 		$1.92K Sell
177
-344
-66% -$3.64K ﹤0.01% 2816
2022
Q4 		$5.85K Buy
521
+71
+16% +$746 ﹤0.01% 2401
2022
Q3 		$5K Buy
450
+9
+2% +$84 ﹤0.01% 2469
2022
Q2 		$4K Sell
441
-53
-11% -$488 ﹤0.01% 2550
2022
Q1 		$5K Buy
494
+185
+60% +$1.81K ﹤0.01% 2514
2021
Q4 		$3K Buy
309
+154
+99% +$1.34K ﹤0.01% 2620
2021
Q3 		$1K Sell
155
-5
-3% -$56 ﹤0.01% 2930
2021
Q2 		$2K Sell
160
-198
-55% -$3.72K ﹤0.01% 2622
2021
Q1 		$7K Buy
358
+276
+337% +$5.25K ﹤0.01% 2027
2020
Q4 		$1K Hold
82
– – ﹤0.01% 2482
2020
Q3 		$1K Buy
82
+23
+39% +$431 ﹤0.01% 2499
2020
Q2 		$1K Buy
+59
New +$1.52K ﹤0.01% 2386
2018
Q3 		– Sell
-200
Closed -$5K – 2001
2018
Q2 		$5K Buy
+200
New +$4.75K ﹤0.01% 1568

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SignatureFD's TBPH Position: Q2 2026 in Review

SignatureFD reduced its Theravance Biopharma (TBPH) stake by 23% in Q2 2026, selling an estimated $1.87K and leaving 387 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

SignatureFD first reported a position in TBPH in Q2 2018 and has held it in 26 quarters since. The position peaked at $9.95K in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • SignatureFD held 387 shares of Theravance Biopharma worth $6.58K as of Q2 2026.
  • SignatureFD sold 113 Theravance Biopharma shares in Q2 2026, an estimated $1.87K.
  • Theravance Biopharma made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2782 holding.
  • SignatureFD first reported a position in Theravance Biopharma in Q2 2018 and has held it in 26 quarters since.
  • SignatureFD's Theravance Biopharma position peaked at $9.95K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.